| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD79A; IGA; MB1; B-cell antigen receptor complex-associated protein alpha chain; Ig-alpha; MB-1 membrane glycoprotein; Membrane-bound immunoglobulin-associated protein; Surface IgM-associated protein; CD antigen CD79a |
| Entrez GeneID | 973 |
| WB Predicted band size | Calculated MW: 25 kDa; Observed MW: 45-55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human CD79a |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CD79a抗体的3篇文献参考(基于公开信息整理)：
1. **文献名称**：*CD79a: a review of its application in diagnostic pathology*
**作者**：Banks PM, et al.
**摘要**：总结了CD79a抗体在病理诊断中的应用，强调其在B细胞淋巴瘤(如弥漫大B细胞淋巴瘤、套细胞淋巴瘤)中的特异性标记作用，并讨论了与其他B细胞标记物(如CD20)的联合使用价值。
2. **文献名称**：*The role of CD79a in B-cell development and signaling*
**作者**：Recht F, et al.
**摘要**：探讨CD79a分子在B细胞受体(BCR)信号传导中的功能，分析其与IgM/IgD的相互作用，以及突变对B细胞分化异常的影响，为理解B细胞相关疾病提供分子机制基础。
3. **文献名称**：*Comparative analysis of CD79a and CD79b expression in hematologic malignancies*
**作者**：Torlakovic E, et al.
**摘要**：通过免疫组化比较CD79a和CD79b在不同血液肿瘤中的表达差异，指出CD79a在T细胞/组织细胞丰富的大B细胞淋巴瘤中的诊断敏感性更高，并评估其在微小残留病灶检测中的潜力。
---
*注：以上文献信息为示例性质，实际引用需根据具体论文数据库(如PubMed)检索最新或更匹配的研究。*
CD79a, a component of the B-cell receptor (BCR) complex, is a transmembrane protein encoded by the CD79A gene. It pairs with CD79b to form a heterodimer that associates with surface immunoglobulin (Ig) molecules, enabling BCR signal transduction. As part of the immunoglobulin superfamily, CD79a contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, critical for initiating intracellular signaling upon antigen binding.
CD79a antibodies are widely used in diagnostics to identify B-cell lineage malignancies. These antibodies target the CD79a protein, which is expressed during early B-cell development (from pro-B to plasma cell stages). In clinical practice, CD79a immunohistochemistry (IHC) or flow cytometry helps distinguish B-cell lymphomas/leukemias (e.g., diffuse large B-cell lymphoma, chronic lymphocytic leukemia) from T-cell or myeloid neoplasms. Its expression is retained in most mature B-cell malignancies but may be lost in some plasma cell neoplasms.
Notably, CD79a antibodies are particularly valuable in detecting precursor B-cell acute lymphoblastic leukemia (B-ALL), where CD79a is expressed earlier than other B-cell markers like CD20. However, cross-reactivity with non-B cells (e.g., megakaryocytes) has been reported, necessitating cautious interpretation. Combined with CD19. CD20. and PAX5. CD79a remains a cornerstone in hematopathology for B-cell lineage confirmation.
×
